InvitroCue Ltd (ASX:IVQ) will collaborate with tropical disease research institutes and pharmaceutical companies to combat malaria.
InvitroCue is using bioanalytics solutions to revolutionize in vitro lab testing for the pharmaceutical and medical industry.
It has a platform technology called "3D cell-based scaffolding" to create multiple assets in toxicology and infectious diseases, as well as, a potential deployment to oncology services.
It is an open and collaborative strategy that involves integrated partnerships and networks between academic infectious diseases institutes and pharmaceutical companies.
The company has signed a research collaboration with Novartis Institute for Tropical Diseases Pte Ltd to investigate the lifecycle of monkey malaria.
In the recent years, drug resistance against malaria has been increasing calling for more research.
The malaria initiative is a part of the company's services pipeline and is set to complete in Q4, 2016.
The leishmaniasis initiative, where InvitroCue is partnering with the London School of Hygiene and Tropical Medicine is also set to complete in Q4, 2016.
The company had $2 million cash at the end of the March quarter.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.